Burosumab for the Treatment of Tumor‐Induced Osteomalacia
Volume: 36, Issue: 4, Pages: 627 - 635
Published: Jan 12, 2021
Abstract
Tumor-induced osteomalacia (TIO) is caused by phosphaturic mesenchymal tumors producing fibroblast growth factor 23 (FGF23) and is characterized by impaired phosphate metabolism, skeletal health, and quality of life. UX023T-CL201 is an ongoing, open-label, phase 2 study investigating the safety and efficacy of burosumab, a fully human monoclonal antibody that inhibits FGF23, in adults with TIO or cutaneous skeletal hypophosphatemia syndrome...
Paper Details
Title
Burosumab for the Treatment of Tumor‐Induced Osteomalacia
Published Date
Jan 12, 2021
Volume
36
Issue
4
Pages
627 - 635
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History